Clinical trials: AMD - Age-Related Macular Degeneration
Age Related Macular Degeneration
Carbidopa-Levodopa in Dry AMD With Geographic Atrophy
From 3 large patient databases, patients diagnosed with AMD who have never taken levodopa(L-DOPA) containing medications have a mean age of diagnosis at 71 years.
- Trial name
- NCT03451500
- Testing
- carbidopa-levodopa
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Snyder, Robert W., M.D., Ph.D., P.C.
Age-related Macular Degeneration
Study of the Discriminating Power of a Blood Biomarker for Omega-3 Polyunsaturated Fatty Acid Content of the Retina for Age-related Macular Degeneration (AMD)
Age-related macular degeneration is a chronic degenerative retinal disease, which can lead to a progressive loss of visual acuity without affecting peripheral vision.
- Trial name
- FATTY (NCT04278300)
- Testing
- blood sampling, faecal sampling (optional)
- Where
- France
- Volunteers
- 205 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
AMD, Age-Related Macular Degeneration
Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration
The objective of this study is to demonstrate the safety and effectiveness of the SING IMT (Smaller Incision New Generation Implantable Miniature Telescope) 3X implant in improving vision in patients with central vision…
- Trial name
- NCT04796545
- Testing
- SING IMT(TM) System, model NG SI IMT 3X
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 68 people
- Sponsor
- VisionCare, Inc.
Dry AMD
Morpho-functional Changes After Oral Supplementation of Antioxidants and Anti-inflammatory Treatment in Age-Related Macular Degeneration.
In patients with AMD a deterioration of the antioxidant mechanisms of the retina is observed and therefore an increase in the production of free radicals responsible for tissue damage.
- Trial name
- MACUPREV (NCT03919019)
- Testing
- Macuprev Group
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione G.B. Bietti, IRCCS
Neovascular Age-related Macular Degeneration
CLN-0046: Treatment of AMD Subjects With OTX-TKI
To evaluate the safety, tolerability and efficacy of OTX-TKI for intravitreal use, in subjects who have neovascular age-related macular degeneration (AMD).
- Trial name
- NCT03630315
- Testing
- OTX-TKI, Anti-VEGF
- Where
- 6 sites in Australia
- Volunteers
- 29 people
- Sponsor
- Ocular Therapeutix, Inc.
Macular Degeneration
Drusen Morphology Changes in Nonexudative Age-related Degeneration After Oral Antioxidants Supplementation
Purpose: To determine drusen morphology (volume and area) changes in nonexudative age-related macular degeneration (AMD) after one year of oral supplementation with AREDS-like formulation.
- Trial name
- NCT02264938
- Testing
- Antioxidant
- Volunteers
- 35 people
- Sponsor
- Germans Trias i Pujol Hospital
Macular Degeneration
EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received EYLEA for Age-Related Macular Degeneration (AMD).
- Trial name
- NCT01756248
- Testing
- Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Japan
- Volunteers
- 3,872 people
- Sponsor
- Bayer
Age Related Macular Degeneration
Molecular Imaging Exploration of Ocular Angiogenic Activity and Evaluation of Its Interest in the Therapeutic Follow-up of Patients With AMD (Age-related Macular Degeneration)
The main objective of this pilot study is to evaluate the ability of 68Ga-NODAGA-RGD PET imaging to demonstrate, in patients with unilateral AMD, a molecular therapeutic response to intraocular antiangiogenic injections at the…
- Trial name
- DMLA-RGD (NCT04005443)
- Testing
- radiopharmaceutical
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
This is a prospective, observational study designed to evaluate the long-term safety and efficacy of RGX-314. Eligible participants are those who were previously enrolled in a clinical study in which they received a single…
- Trial name
- RGX-314 SRLTFU (NCT03999801)
- Testing
- RGX-314
- Where
- 9 sites in United States
- Volunteers
- 865 people
- Sponsor
- AbbVie
Age Related Macular Degeneration
RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration
This study is a single-center, open label, 4-month study, designed to evaluate the safety and treatment efficacy of RBM-007 in patients with intraretinal or subretinal edema due to previously untreated neovascular AMD.
- Trial name
- TEMPURA (NCT04895293)
- Testing
- RBM-007 Injectable Solution
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Maturi, Raj K., M.D., P.C.
Macular Degeneration
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
The purpose of this study is to determine the safety and efficacy of different dosage regimens of pazopanib eye drops for the treatment of neovascular age-related macular degeneration.
- Trial name
- NCT01134055
- Testing
- pazopanib eye drops, ranibizumab intravitreal injection
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 510 people
- Sponsor
- GlaxoSmithKline
Age Related Macular Degeneration
Retinal Pigment Epithelium Safety Study For Patients In B4711001
This is a safety follow-up study. Patients enrolled in B4711001 will be followed for a further 4 years with regular visits to assess safety.
- Trial name
- NCT03102138
- Where
- 2 sites in United Kingdom
- Volunteers
- 10 people
- Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
Neovascular Age-related Macular Degeneration, Macular Oedema Secondary to RVO
A Trial to Evaluate the Safety and Usability of the SB15 PFS in Trial Participants With AMD, Macular Oedema Secondary to RVO, or Diabetic Macular Oedema
This is an open label, multicenter, Phase II trial to evaluate the safety and usability of the pre-filled syringe (PFS) of SB15 (Aflibercept biosimilar).
- Conditions
- Neovascular Age-related Macular Degeneration, Macular Oedema Secondary to RVO, Diabetic Macular Oedema
- Trial name
- NCT07844343
- Testing
- SB15 PFS
- Where
- 3 sites in South Korea
- Volunteers
- 33 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Age Related Macular Degeneration
WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment Examination
The purpose of this study is to evaluate the safety, tolerability, and effects of investigational drug AL-39324 for the treatment of wet AMD.
- Trial name
- NCT00992563
- Testing
- AL-39324 ophthalmic suspension, Ranibizumab 10 mg/mL
- Volunteers
- 35 people
- Sponsor
- Alcon Research
Pain
Intravitreal Injection Site and Perceived Pain
The objective of this study is to explore the perception of pain during intravitreal injection related to the distance of the entry site from the limbus.
- Trial name
- NCT05640895
- Testing
- Intravitreal injection site
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Neovascular Age-related Macular Degeneration
Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD
The purpose of this prospective interventional study is to assess whether adjunctive verteporfin photodynamic therapy (PDT) is effective for the treatment of persistent disease activity in neovascular age-related macular…
- Trial name
- NCT02457026
- Testing
- Aflibercept, Triamcinolone Acetonide, Verteporfin
- Where
- United States
- Sponsor
- Duke University
Neovascular Age-related Macular Degeneration
Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)
The purpose of this clinical study is to evaluate the efficacy and safety of two different levels of conbercept intravitreal (IVT) injection as compared to the approved vascular endothelial growth factor (VEGF) antagonist active…
- Trial name
- NCT03577899
- Testing
- 0.5 mg Conbercept Intravitreal Injection, 1.0 mg Conbercept Intravitreal Injection, 2.0 mg Aflibercept Intravitreal Injection
- Where
- 179 sites in United States, Argentina and 20 more
- Volunteers
- 1,157 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Neovascular Age-related Macular Degeneration (nAMD)
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe
This was an open-label, single arm, multicenter, Phase IIIb study in subjects with (wet) nAMD, eligible for IVT aflibercept treatment.
- Trial name
- NCT05161806
- Testing
- SOK583A1 (40 mg/mL), Prefilled Syringe (PFS)
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Sandoz
Macular Degeneration
Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD
The purpose of this trial is to assess the ocular and systemic safety and tolerability of a single intravitreal injection of VEGF Trap in patients with subfoveal choroidal neovascularization (CNV) due to AMD.
- Trial name
- NCT00320775
- Testing
- VEGF Trap
- Where
- 8 sites in United States
- Volunteers
- 51 people
- Sponsor
- Regeneron Pharmaceuticals
Macular Degeneration
Complications of Age-Related Macular Degeneration Prevention Trial
To determine whether application of low-intensity laser treatment of eyes with drusen in the macula can prevent later complications of age-related macular degeneration and thereby preserve visual function.
- Trial name
- CAPT (NCT00000167)
- Testing
- Low-Intensity Laser Treatment
- Where
- 24 sites in United States
- Volunteers
- 1,052 people
- Sponsor
- National Eye Institute (NEI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.